Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization

Jonathan F. Russell; Thomas A. Albini; Audina M. Berrocal; Sander R. Dubovy; Philip J. Rosenfeld; William E. Smiddy; Jayanth Sridhar; Justin H. Townsend; Harry W. Flynn

doi:10.1016/j.oret.2019.09.008

Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization

Jonathan F. Russell, Thomas A. Albini, Audina M. Berrocal, Sander R. Dubovy, Philip J. Rosenfeld, William E. Smiddy, Jayanth Sridhar, Justin H. Townsend, Harry W. Flynn

Ophthalmology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	226-228
Number of pages	3
Journal	Ophthalmology Retina
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.oret.2019.09.008
State	Published - Feb 2020

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/j.oret.2019.09.008

Cite this

Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization. / Russell, Jonathan F.; Albini, Thomas A.; Berrocal, Audina M.; Dubovy, Sander R.; Rosenfeld, Philip J.; Smiddy, William E.; Sridhar, Jayanth; Townsend, Justin H.; Flynn, Harry W.

In: Ophthalmology Retina, Vol. 4, No. 2, 02.2020, p. 226-228.

Research output: Contribution to journal › Article › peer-review

@article{b3d519f4d05f494494bec7b8247cfc6a,

title = "Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization",

author = "Russell, {Jonathan F.} and Albini, {Thomas A.} and Berrocal, {Audina M.} and Dubovy, {Sander R.} and Rosenfeld, {Philip J.} and Smiddy, {William E.} and Jayanth Sridhar and Townsend, {Justin H.} and Flynn, {Harry W.}",

note = "Funding Information: Supported in part by Research to Prevent Blindness, Inc, New York, New York; and the National Eye Institute, National Institutes of Health, Bethesda, Maryland (center core grant no.: P30EY014801). The funding organizations had no role in the design or conduct of this research. Financial Disclosure(s): The author(s) have made the following disclosure(s): T.A.A.: Consultant Allegro Ophthalmics, Beaver Visitec, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech, Jannsen Biotech, Notal Vision, Novartis, Santen, Valeant. P.J.R.: Consultant ? Apellis Pharmaceuticals, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, Healios K.K., Hemera Biosciences, F. Hoffmann-La Roche Ltd, Isarna Pharmaceuticals, Lin Bioscience, NGM Biopharmaceuticals, Ocunexus Therapeutics, Ocudyne, Unity Biotechnology; Financial support ? Carl Zeiss Meditec, Inc, Genentech, Boehringer-Ingelheim; Equity interest ? Apellis, Verana Health, Ocudyne. Obtained funding: None",

year = "2020",

month = feb,

doi = "10.1016/j.oret.2019.09.008",

language = "English (US)",

volume = "4",

pages = "226--228",

journal = "Ophthalmology Retina",

issn = "2468-7219",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Anti–Vascular Endothelial Growth Factor Therapy for Choroidal Rupture-Associated Choroidal Neovascularization

AU - Russell, Jonathan F.

AU - Albini, Thomas A.

AU - Berrocal, Audina M.

AU - Dubovy, Sander R.

AU - Rosenfeld, Philip J.

AU - Smiddy, William E.

AU - Sridhar, Jayanth

AU - Townsend, Justin H.

AU - Flynn, Harry W.

N1 - Funding Information: Supported in part by Research to Prevent Blindness, Inc, New York, New York; and the National Eye Institute, National Institutes of Health, Bethesda, Maryland (center core grant no.: P30EY014801). The funding organizations had no role in the design or conduct of this research. Financial Disclosure(s): The author(s) have made the following disclosure(s): T.A.A.: Consultant Allegro Ophthalmics, Beaver Visitec, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech, Jannsen Biotech, Notal Vision, Novartis, Santen, Valeant. P.J.R.: Consultant ? Apellis Pharmaceuticals, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, Healios K.K., Hemera Biosciences, F. Hoffmann-La Roche Ltd, Isarna Pharmaceuticals, Lin Bioscience, NGM Biopharmaceuticals, Ocunexus Therapeutics, Ocudyne, Unity Biotechnology; Financial support ? Carl Zeiss Meditec, Inc, Genentech, Boehringer-Ingelheim; Equity interest ? Apellis, Verana Health, Ocudyne. Obtained funding: None

PY - 2020/2

Y1 - 2020/2

UR - http://www.scopus.com/inward/record.url?scp=85078657403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078657403&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2019.09.008

DO - 10.1016/j.oret.2019.09.008

M3 - Article

AN - SCOPUS:85078657403

VL - 4

SP - 226

EP - 228

JO - Ophthalmology Retina

JF - Ophthalmology Retina

SN - 2468-7219

IS - 2

ER -